The proliferation of M-NFS-60 cells treated with increasing concentrations of hG-CSF was assessed. After 72 hour treatment with hG-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hG-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hG-CSF and staining overnight with Coomassie Blue.
Western blot analysis of extracts from M-NSF-60 cells untreated or treated with hG-CSF for 15 minutes, using Phospho-Stat3 (Tyr705) (D3A7) Rabbit mAb #9145 (upper) or Stat3 Antibody #9132 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of 40 mM phosphate pH 4.0 containing 250 mM NaCl and 20 μg BSA per 1 μg hG-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of 40 mM phosphate pH 4.0 containing 250 mM NaCl.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hG-CSF. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1μg hG-CSF.
The bioactivity of recombinant hG-CSF was determined in a M-NFS-60 cell proliferation assay. The ED50 of each lot is between 20-150 pg/ml.
Recombinant hG-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,986. DTT-reduced and non-reduced protein migrate as 18 kDa polypeptides. The expected amino-terminal TPLGP of recombinant hG-CSF was verified by amino acid sequencing.
Recombinant human G-CSF (hG-CSF) Thr31-Pro204 (Accession #NP_757373) was expressed in human 293 cells at Cell Signaling Technology.
G-CSF is a hematopoietic cytokine essential for neutrophil development, survival, and egress from bone marrow (1-4). Macrophages and monocytes are the predominant producers of G-CSF (3) and endothelial cells, fibroblasts and neuronal cells can produce G-CSF in response to inflammatory stimuli (3). G-CSF inhibits apoptosis in neutrophils and neurons (4,5). G-CSF stimulates proliferation and differentiation of neuronal progenitor cells (5). G-CSF binding to G-CSFR induces receptor dimerization and activation of Jak1/2 tyrosine phosphorylation (3,6). Signaling is through Stat3, ERK, p38, and Akt (5,6). Absence of functional G-CSF or its receptor in humans and mice causes neutropenia (7,8).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.